Product
PCV20
Aliases
0.5 ml dose of PCV20
4 clinical trials
5 indications
Indication
Pneumococcal VaccinesIndication
Pneumococcal InfectionIndication
COVID-19Indication
Pneumococcal InfectionsIndication
lymphomaClinical trial
Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric VaccinesStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve AdultsStatus: Completed, Estimated PCD: 2023-05-18
Clinical trial
Safety and Immunogenicity of Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: a Four-arm, Double-blind, Non-inferiority TrialStatus: Not yet recruiting, Estimated PCD: 2023-07-01
Clinical trial
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 TherapyStatus: Recruiting, Estimated PCD: 2025-07-31